Developing New Generation Medicines for Depression, Pain, Social Anxiety and Other Central Nervous System (CNS) Diseases and Disorders with high unmet need
AV-101, our oral N-methyl-D-aspartate receptor glycine B (NMDAR GlyB) antagonist, belongs to a new generation of investigational medicines in neuropsychiatry known as glutamate receptor modulators having the potential to treat Major Depressive Disorder (MDD) faster than current FDA-approved antidepressants commonly known as SSRIs and SNRIs, which target the neurotransmitters serotonin and/or norepinephrine, respectively.
Learn About AV-101 AV-101 Mechanism of Action Video